Fiinu Plc (BANK) provided an update on the planned launch of its Plugin Overdraft®, in partnership with Manx Financial Group Plc (MFX) and its subsidiary Conister Bank Limited. Fiinu notes the recent update by MFX, where it confirmed Conister had received regulatory approval for the Plugin Overdraft® product, and confirms that the parties are undergoing user acceptance testing (“UAT”) of the agreed minimum viable product (“MVP”). All Fiinu-side final MVP configuration delivery dates are scheduled to be delivered this quarter. Further to these deliverables, Fiinu intends to develop an outbound third-party payment interface for Conister. The Board notes that most of the core banking, AI-driven underwriting and servicing functionality is already operational in test environment. Whilst both parties had planned a Q1 2026 launch, there is now recognition that these final requirements mean that Conister is unlikely to launch until Q2 2026.
Comment: While the market may be temporarily disappointed by the delay being flagged here, it is still the case that we should be rejoicing that BANK has managed to get itself in position to roll out its strategy with a decent partner.
IMC Exploration Group plc (IMC), the London-listed exploration company based in Ireland, announced results showing free gold in quartz veins intersected by drillhole 24-2551-01 from a laboratory study of its 2024 drilling at its Boley prospect in Prospecting Licence (PL) 2551 in Co. Wexford Ireland. Drillhole 24-2551-01 extended the strike extent of known gold mineralization at the Boley prospect by 150m to the northeast by intersecting 1m grading 5.8g/t Au in an upper zone and 1m grading 1.1g/t Au in a lower zone (IMC News Release 21st March 2024). An historic IMC drillhole from the Boley prospect intercepted 1.5m grading 354g/t Au near surface.
Comment: IMC serves up a good enough update to finesse the recent sharp rally in the stock, and most likely continue it up another leg. Above recent support at 1.5p, a retest of this month’s peak of 2.85p seems possible by the end of next month.
Convatec Group (CTEC) announced its FY25 Results. Strong delivery drives revenue growth, margin progress & mid-teens adjusted EPS growth. Upgrading medium-term organic growth target to 6-8%. In line with guidance.
Comment: There would appear to be a disconnect between the latest update from CTEC, which suggests that the company is buzzing like a bee, and the share price action still stuck at the lower end of the range, 220p to 250p.
Avacta Therapeutics (AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today published new data which demonstrates the favorable delivery profile and advantages of its proprietary pre|CISION platform’s compared to a marketed antibody drug conjugate (ADC). The data analysis compares pre|CISION FAP-cleavable payload delivery with that of Enhertu®, a protease cleavable-linker ADC, approved for both breast cancer and gastric cancer indications (an AstraZeneca/Daiichi Sankyo product, trastuzumab-deruxtecan (T-Dxd), an exatecan-derivative ADC). Avacta expects to initiate the Phase 1 clinical trial of its FAP-Exd (AVA6103) program in Q1 2026.
Comment: Progress / jam tomorrow is what is critical to the share price of AVCT, and ideally to get it back up to the 80p plus dizzy heights of the past year. Chasing a Phase 1 clinical trial may just be enough.
Alkemy Capital Investments plc (ALK), announced that its wholly owned subsidiary Tees Valley Lithium, has agreed Heads of Terms with Wates Construction Limitedfor a Pre-Construction Services Agreement. Further to the recently completed FEED study, a preferred project site in Teesside is being acquired. All core workstreams remain aligned to the previously announced timelines.
Comment: ALK serves up one of its periodic “we’re getting there” RNS updates to keep the fires burning of the extended rally that the company has been in for much of the past year. Chart wise we may still dare to dream of a 500p target by the end of next
Georgina Energy (GEX) advised it has received the draft Aboriginal Land Rights Agreement (ALRA) from the Central Land Council (CLC) to facilitate the granting of EPA155 Mt Winter which will lead to the 100% ownership of Oilco Pty Ltd, the current tenement holders. The Agreement is being reviewed by Georgina and execution is anticipated subject to Traditional Landowners approval.
Comment: While the momentum here at GEX appears to be perfectly fine and dandy, it is the case that its main detractor is still psychotically throwing stones. Ideally the shares remain above the key 5p level for long enough for the company to raise the cash it apparently needs. Indeed, the cash that most listed companies need.
TPXimpact Holdings PLC (TPX), a leading technology-enabled services company focused on people-powered digital transformation, provided an update on trading for the third quarter ended 31 December 2025, upgrades EBITDA guidance for FY26, and confirms £110m of new business year to date. Following strong trading in Q3 and continued momentum during Q4, the Group is upgrading its outlook for the full year ending 31 March 2026 as follows: Adjusted EBITDA: Upgrading year-end guidance to not less than £7m (previously £6-7m). Net Debt guidance confirmed at below £6m, leverage reduced to c.0.85x Net Debt/EBITDA.
Comment: Not so much a rising star, but one that has risen, and is continuing to re-rate in a very positive way. The positivity is typical of when the London market is caught with its trousers down regarding a company that goes from being a hopeful to a winner.
N4 Pharma plc (N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announced that it is expanding its pipeline to transition to a therapeutic biotechnology company focused on the development of innovative RNA-based therapeutics as well as progressing its novel RNA delivery platform Nuvec®. The Company has submitted a preliminary patent filing for a novel dual-acting siRNA targeting the reduction of cardiovascular risk. To implement this accelerated strategy, the Company has appointed Dr David H Solomon as Chief Executive Officer, and it is proposed that the Company will be renamed Thalia Therapeutics plc. In identifying David as his successor, Nigel Theobald, the Company founder, has stepped down as Chief Executive Officer and a director of the Company with immediate effect to enjoy his retirement.
Comment: It would appear to be all change at N4P, including the name, as the company is perhaps keen to transform itself from being a biotech hopeful, to one that could be a meaningful play, at least one that is valued rather more than £4,4m. There is plenty of work for the new CEO to do.
